Literature DB >> 8486952

Heterogeneity in filarial-specific immune responsiveness among patients with lymphatic obstruction.

P J Lammie1, D G Addiss, G Leonard, A W Hightower, M L Eberhard.   

Abstract

The relationship between chronic obstructive disease and antifilarial immune responsiveness was studied in the Haitian community of Leogane, where Wuchereria bancrofti is endemic. Differences in sex ratios and in the prevalence of microfilaremia were observed between patients with hydrocele and those with lymphedema or elephantiasis of the lower limb. Only 2 of 84 patients with limb involvement (74 women, 10 men) were microfilaremic compared with 25 of 42 men with hydrocele. Microfilaria-positive men with hydrocele had significantly lower IgG2 and proliferative responses to filarial antigen than did amicrofilaremic men with hydrocele or individuals with lymphedema or elephantiasis. Parasite-specific cellular responses of amicrofilaremic individuals with obstructive disease were greater, although not significantly so, than those of amicrofilaremic asymptomatic members of the community. These results are compatible with the hypothesis that development of obstructive disease of the lymphatics has an immune component in amicrofilaremic persons.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486952     DOI: 10.1093/infdis/167.5.1178

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Regulation of parasite antigen-driven immune responses by interleukin-10 (IL-10) and IL-12 in lymphatic filariasis.

Authors:  S Mahanty; M Ravichandran; U Raman; K Jayaraman; V Kumaraswami; T B Nutman
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

2.  Differences in the frequency of cytokine-producing cells in antigenemic and nonantigenemic individuals with bancroftian filariasis.

Authors:  A B de Almeida; M C Silva; C Braga; D O Freedman
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

3.  Feasibility and effectiveness of basic lymphedema management in Leogane, Haiti, an area endemic for bancroftian filariasis.

Authors:  David G Addiss; Jacky Louis-Charles; Jacquelin Roberts; Frederic Leconte; Joyanna M Wendt; Marie Denise Milord; Patrick J Lammie; Gerusa Dreyer
Journal:  PLoS Negl Trop Dis       Date:  2010-04-20

4.  Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2.

Authors:  M Yazdanbakhsh; W A Paxton; A Brandenburg; R Van Ree; M Lens; F Partono; R M Maizels; M E Selkirk
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

5.  Histopathologic improvement with lymphedema management, Léogâne, Haiti.

Authors:  Susan F Wilson; Jeannette Guarner; Alix L Valme; Jacky Louis-Charles; Tara L Jones; David G Addiss
Journal:  Emerg Infect Dis       Date:  2004-11       Impact factor: 6.883

6.  Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature.

Authors:  David G Addiss; Molly A Brady
Journal:  Filaria J       Date:  2007-02-15

7.  Translating Research into Reality: Elimination of Lymphatic Filariasis from Haiti.

Authors:  Patrick J Lammie; Mark L Eberhard; David G Addiss; Kimberly Y Won; Madsen Beau de Rochars; Abdel N Direny; Marie Denise Milord; Jack Guy Lafontant; Thomas G Streit
Journal:  Am J Trop Med Hyg       Date:  2017-10       Impact factor: 2.345

8.  Financial burden impact quality of life among lymphatic Filariasis patients.

Authors:  Samuel Opoku Asiedu; Alexander Kwarteng; Emmanuel Kobla Atsu Amewu; Priscilla Kini; Bill Clinton Aglomasa; John Boulard Forkuor
Journal:  BMC Public Health       Date:  2021-01-21       Impact factor: 3.295

Review 9.  Lymphatic Filariasis: A Systematic Review on Morbidity and Its Repercussions in Countries in the Americas.

Authors:  Zulma M Medeiros; Amanda V B Vieira; Amanda T Xavier; Gilberto S N Bezerra; Maria de Fátima C Lopes; Cristine V Bonfim; Ana M Aguiar-Santos
Journal:  Int J Environ Res Public Health       Date:  2021-12-28       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.